Nod from Mexico, a boost for Biocon

| Updated on January 23, 2018 Published on April 09, 2015


Shares of Biocon will remain in focus on Friday, as the company strengthens its presence in Mexico. In a post-market hour disclosure, Biocon said it has received approval from Cofepris, the Mexican health authority, for insulin glargine through its partner PiSA Farmaceutica. Through the tie-up, Biocon will introduce Galactus, the long acting insulin glargine in Mexico, which has a disease prevalence of 12 per cent, the second highest in the world.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 09, 2015
This article is closed for comments.
Please Email the Editor